Compare Repligen Corporation Common Stock (RGEN) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TKO Group Holdings Inc — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while TKO Group Holdings Inc trades at $173.56 (market cap $12.71B). The key difference: Repligen Corporation Common Stock and TKO Group Holdings Inc are close in size by market cap, and TKO Group Holdings Inc pays a 1.82% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TKO Group Holdings Inc for 31 Days on average.
| RGEN | TKO | |
|---|---|---|
Market Cap | $11.14B | $12.71B |
Volume | 1,259,263 | 835,872 |
Sector | Health | Media |
52-Week High | $194.57 | $224.96 |
52-Week Low | $102.87 | $172.38 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $11.02B | $17.07B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TKO trades at $173.86, near a 52-week low, with a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though profitability remains modest with a net margin of 4.33%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $227.00 and 89% buy ratings, but recent institutional selling and technical weakness suggest near-term caution.
The outlook is cautiously optimistic; strong media rights and franchise value underpin long-term growth, but high valuation multiples and recent price decline highlight execution risks. Investors should weigh robust analyst confidence against technical bearishness and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
